• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American journal of applied sciences >Anti-β2 Glycoprotein-I Antibody in Acute Myocardial Infarction
【24h】

Anti-β2 Glycoprotein-I Antibody in Acute Myocardial Infarction

机译：抗β2糖蛋白I抗体在急性心肌梗死中的应用

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Problem statement: Ischemic cardiac manifestations have been reported in a various percentage of patients with anti-phospholipid antibodies. Data concerning the relation between anti-Phospholipid (aPL) antibodies and myocardial infarction in subjects without evidence of overt autoimmune disease are conflicting. Anti-beta2 glycoprotein-1 (anti-beta2-GPI) antibody is detected in various diseases like rheumatoid arthritis, systemic lupus erythematosus and anti-phospholipid antibody syndrome. The study of anti-beta2-GPI antibody in Acute Myocardial Infarction (AMI) might shed light on etiologic mechanisms in the pathogenesis of acute coronary syndromes. The purpose of the present study was to determine association of plasma aPL antibodies, namely, anti-beta2-GPI antibodies, with AMI. This study was designed to investigate whether prevalence of anti-beta2-GPI antibodies, in patients who had acute myocardial infarction and to analyze their relationship with traditional cardiovascular risk factors. Approach: We investigated the prevalence of anti-beta2-GPI IgG in a well characterized group of patients with AMI as a case group. Sera from 74 patients with AMI and from 76 healthy subjects, matched for age and sex as a control group. Using ELISA to evaluate the presence of IgG isotype of anti-beta2-GPI autoantibodies in their sera. Results: The prevalence of anti-beta2-GPI IgG in the control group (10.50%) resulted significantly lower than in patients with AMI (37.80%) (p<0.005). There was significant difference between positive anti-P2-GPI test in patients with STEMI and those with NSTEM1 (66.7% Vs 36.4%), (p = 0.020). Conclusion: Our findings suggest that anti-beta2-GPI IgG antibodies seemed to behave as independent risk factors for myocardial infarction, which may represent a link between autoimmunity and atherosclerosis in patients with acute myocardial infarction. Further studies with bigger patients are needed to explore association of anti-P2-GPI IgG with STEMI and NSTEM1.
机译：问题陈述：在各种百分比的抗磷脂抗体患者中都报告了缺血性心脏表现。在没有明显的自身免疫性疾病证据的受试者中，有关抗磷脂（aPL）抗体与心肌梗死之间关系的数据存在矛盾。在各种疾病（例如类风湿性关节炎，系统性红斑狼疮和抗磷脂抗体综合征）中都检测到了抗β2糖蛋白1（anti-beta2-GPI）抗体。抗β2-GPI抗体在急性心肌梗塞（AMI）中的研究可能有助于阐明急性冠状动脉综合征的发病机制。本研究的目的是确定血浆aPL抗体（即抗β2-GPI抗体）与AMI的关联。本研究旨在调查急性心肌梗死患者中是否存在抗β2-GPI抗体，并分析其与传统心血管危险因素的关系。方法：我们调查了特征明确的AMI患者组（病例组）中抗β2-GPIIgG的患病率。年龄和性别相匹配的74例AMI患者和76例健康受试者的血清作为对照组。使用ELISA评估其血清中抗β2-GPI自身抗体IgG同种型的存在。结果：对照组中抗β2-GPIIgG的患病率（10.50％）显着低于AMI患者（37.80％）（p <0.005）。 STEMI患者和NSTEM1患者的抗P2-GPI阳性试验之间有显着差异（66.7％vs 36.4％）（p = 0.020）。结论：我们的发现表明抗β2-GPIIgG抗体似乎是心肌梗死的独立危险因素，这可能代表急性心肌梗死患者自身免疫性与动脉粥样硬化之间的联系。需要对更大的患者进行进一步研究，以探索抗P2-GPI IgG与STEMI和NSTEM1的关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号